A detailed history of Amalgamated Bank transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 2,147 shares of FULC stock, worth $9,768. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,147
Previous 2,147 -0.0%
Holding current value
$9,768
Previous $13,000 38.46%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$5.98 - $9.31 $12,839 - $19,988
2,147 New
2,147 $13,000
Q1 2023

May 02, 2023

SELL
$2.83 - $13.99 $1,896 - $9,373
-670 Reduced 11.71%
5,054 $14,000
Q4 2022

Feb 10, 2023

BUY
$5.01 - $8.35 $8,496 - $14,161
1,696 Added 42.11%
5,724 $42,000
Q2 2022

Aug 15, 2022

BUY
$4.2 - $24.0 $2,956 - $16,896
704 Added 21.18%
4,028 $20,000
Q1 2022

Jun 30, 2022

BUY
$9.96 - $23.65 $33,107 - $78,612
3,324 New
3,324 $79,000

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $237M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.